NR1H4 and metabolic dysfunction-associated steatohepatitis: This study rigorously compared multiple doses of the FXR agonists OCA and INT-787 on plasma biomarkers, quantitative histologic disease parameters, and hepatic gene expression profiles in the AMLN diet–induced and biopsy-confirmed mouse model of NASH.